RxDoctor Payments Data

Avidah Rudberg, MD

Urology · Bonita Springs, FLNPI 1639124779

Payments from drug & device makers

$1,180in general payments, 2019–2025

Across 37 payments — averaging $31.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$336
  • Johnson & Johnson$198
  • Laborie Medical Technologies Corp.$146
  • Janssen Scientific Affairs, LLC$134
  • Coloplast$85
  • Aytu Biopharma, Inc.$70
  • plus $212 from 8 others

What the payments were for

  • Food & beverage$89176%
  • Education$28924%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,180 in reported general payments places this provider in the 25th percentile of 935 urology providers in Florida.

See all urology providers in Florida

Medicare billing

Part B allowed, 2024
$480,853
Medicare patients
359
Services billed
5,573

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron494$236,456
MyrbetriqMirabegron430$194,438
TrelstarTriptorelin Pamoate35$89,073
Testosterone108$22,262
Mirabegron ErMirabegron21$7,780
Alfuzosin Hcl ErAlfuzosin Hcl837$6,581
ToviazFesoterodine Fumarate13$3,547
RapafloSilodosin12$3,143
Imipramine Hcl216$1,967
Potassium Citrate ErPotassium Citrate84$1,913
Cefpodoxime Proxetil35$1,543
Tamsulosin Hcl208$1,334
Tolterodine Tartrate ErTolterodine Tartrate26$885
Fesoterodine Fumarate ErFesoterodine Fumarate18$860
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip29$531

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$336$194,438430 claims
PfizerToviaz$63$3,54713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 935 urology providers in Florida.

Other urology in Bonita Springs

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →